575 related articles for article (PubMed ID: 26019129)
21. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
; Benavente OR; Hart RG; McClure LA; Szychowski JM; Coffey CS; Pearce LA
N Engl J Med; 2012 Aug; 367(9):817-25. PubMed ID: 22931315
[TBL] [Abstract][Full Text] [Related]
22. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
23. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
[TBL] [Abstract][Full Text] [Related]
24. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Yi X; Zhou Q; Wang C; Lin J; Chai Z
J Neurol; 2018 Oct; 265(10):2396-2403. PubMed ID: 30128710
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of
Kim JH; Lee SJ; Cha JJ; Park JH; Hong SJ; Ahn TH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
J Am Heart Assoc; 2024 May; 13(10):e032248. PubMed ID: 38761068
[TBL] [Abstract][Full Text] [Related]
26. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
[TBL] [Abstract][Full Text] [Related]
28. Ticagrelor Aspirin vs Clopidogrel Aspirin in
Wang A; Meng X; Tian X; Zuo Y; Bath PM; Li H; Xie X; Jing J; Lin J; Wang Y; Zhao X; Liu L; Li Z; Jiang Y; Xu J; Wang F; Chen W; Cao M; Li J; Wang Y
Neurology; 2023 Jan; 100(5):e497-e504. PubMed ID: 36535779
[TBL] [Abstract][Full Text] [Related]
29. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
[TBL] [Abstract][Full Text] [Related]
30. One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in
Meng X; Wang A; Tian X; Johnston C; Li H; Bath PM; Xu Q; Zhang Y; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Wang Y
Neurology; 2024 Feb; 102(3):e207809. PubMed ID: 38181311
[TBL] [Abstract][Full Text] [Related]
31. [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
Li G; Chen J; Xu Z; Wang Y; Ding N; Peng L; Zhang C; Shao Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Dec; 34(6):839-843. PubMed ID: 29188612
[TBL] [Abstract][Full Text] [Related]
32. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
34. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
35. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
36. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
37. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
38. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
